Investing.com - Financial Markets Worldwide

Aurisco Pharmaceutical Co Ltd (605116)

Shanghai
Currency in CNY
23.20
-0.18(-0.77%)
Delayed Data·
605116 Scorecard
Full Analysis
Has raised its dividend for 5 consecutive years
605116 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
23.0423.43
52 wk Range
18.7026.49
Key Statistics
Edit
Bid/Ask
23.20 / 23.21
Prev. Close
23.38
Open
23.32
Day's Range
23.04-23.43
52 wk Range
18.7-26.49
Volume
1.4M
Average Volume (3m)
3.66M
1-Year Change
-0.09%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
605116 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 8
Analysts anticipate sales growth in the current year
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Aurisco Pharmaceutical Co Ltd Company Profile

Aurisco Pharmaceutical Co.,Ltd. engages in research, manufacturing, and marketing of pharmaceutical intermediates, specialty active pharmaceutical ingredients (API’s), and formulations catering to the pharmaceutical market worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, and chronic obstructive pulmonary disease; eplerenone preparations are used for the treatment of hypertension and heart failure; bepedalic acid preparations are used for the treatment of hypercholesterolemia or atherosclerotic cardiovascular diseases; tenofovir used for the treatment of HIV-1 infection and chronic hepatitis B; pregabalin preparations are used to treat neuropathic pain, fibromyalgia, epilepsy, etc.; brivaracetam preparations are used to treat epilepsy; abiraterone acetate preparation for the treatment of prostate cancer; enzalutamide preparation for the treatment of prostate cancer; and dydrogesterone preparations are used to treat dysmenorrhea, endometriosis, irregular menstrual cycle, etc. In addition, the company provides contract manufacturing services and related development works for chemicals, intermediates, and API’s. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
1784
Market
China

Compare 605116 to Peers and Sector

Metrics to compare
605116
Peers
Sector
Relationship
P/E Ratio
24.2x30.5x−0.5x
PEG Ratio
1.03−0.170.00
Price/Book
3.9x3.2x2.6x
Price / LTM Sales
6.2x4.7x3.3x
Upside (Analyst Target)
19.8%10.1%43.3%
Fair Value Upside
Unlock17.8%6.9%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.99%
Dividend Yield
1.24%
Industry Median 1.51%
Annualised payout
0.29
Paid annually
5-Years Growth
-
Growth Streak
Unlock

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
0.30 / --
Revenue / Forecast
402.00M / --
EPS Revisions
a
a
Unlock
Last 90 days

605116 Income Statement

FAQ

What Stock Exchange Does Aurisco Pharmaceutical Co Trade On?

Aurisco Pharmaceutical Co is listed and trades on the Shanghai Stock Exchange stock exchange.

What Is the Stock Symbol for Aurisco Pharmaceutical Co?

The stock symbol for Aurisco Pharmaceutical Co is "605116."

What Is the Aurisco Pharmaceutical Co Market Cap?

As of today, Aurisco Pharmaceutical Co market cap is 9.50B.

What Is Aurisco Pharmaceutical Co's Earnings Per Share (TTM)?

The Aurisco Pharmaceutical Co EPS (TTM) is 0.99.

When Is the Next Aurisco Pharmaceutical Co Earnings Date?

Aurisco Pharmaceutical Co will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is 605116 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Aurisco Pharmaceutical Co Stock Split?

Aurisco Pharmaceutical Co has split 0 times.

How Many Employees Does Aurisco Pharmaceutical Co Have?

Aurisco Pharmaceutical Co has 1784 employees.

What is the current trading status of Aurisco Pharmaceutical Co (605116)?

As of 11 Aug 2025, Aurisco Pharmaceutical Co (605116) is trading at a price of 23.20, with a previous close of 23.38. The stock has fluctuated within a day range of 23.04 to 23.43, while its 52-week range spans from 18.70 to 26.49.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.